MDT Stock Recent News

Medtronic (MDT) concluded the recent trading session at $82.60, signifying a -0.12% move from its prior day's close.

Bill George, executive fellow at Harvard Business School and former CEO and chairman of Medtronic, joins Market Domination Overtime to discuss the most recent tariff developments. George emphasizes how President Trump's tariff policies and policy adjustments erode other nations' trust in the United States.

Dividend stocks are great long-term investments. They've outperformed non-dividend-paying stocks by more than 2-to-1 over the long term.

In the latest trading session, Medtronic (MDT) closed at $88.86, marking a +0.42% move from the previous day.

Medtronic (MDT 2.62%) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly.

Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.

Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT 0.88%), one of the largest and most diversified medical device makers.

Medtronic (MDT) concluded the recent trading session at $88.98, signifying a +0.85% move from its prior day's close.

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.

Boston Scientific, Abbott and Medtronic are included in this Analyst Blog.